CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the redirecting of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, a panel of experts come together to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types.
Learning objectives:
-Molecular mechanism of PD-L1 regulation in cancer cells
-Immunosuppressive nature of triple negative breast cancer
-Using in vitro co-culture system to analyze T cell-mediated cancer cell killing effect
-Complete the form below to access this webinar recording.
Bruce Levine, PhD, Abramson Cancer Center, University of Pennsylvania
Watch the webinar!